Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach

Documenti analoghi

• Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach
  di: Rune Viig Overgaard, et al.
  Pubblicazione: (2026)
• Comment on ‘Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach’
  di: Vijay Kumar K. V., et al.
  Pubblicazione: (2026)
• Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity
  di: Andreea Ciudin, et al.
  Pubblicazione: (2026)
• Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population‐Adjusted Indirect Treatment Comparison
  di: Wojciech Michalak, et al.
  Pubblicazione: (2026)
• SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials
  di: Pierre Bel Lassen, et al.
  Pubblicazione: (2026)